Want to see HK:3839 full AI Analyst Report?
3839 Stock Chart & Stats
HK$6.79
HK$0.07(4.61%)
At close: 4:00 PM EST
HK$6.79
HK$0.07(4.61%)
Day’s Range― - ―
52-Week RangeHK$4.52 - HK$10.15
Previous CloseN/A
Volume9.50K
Average Volume (3M)166.49K
Market Cap
HK$2.29B
Enterprise ValueHK$272.30M
Total Cash (Recent Filing)HK$35.49M
Total Debt (Recent Filing)HK$59.09M
Price to Earnings (P/E)9.2
Beta1.49
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding240,718,300
10 Day Avg. Volume121,886
30 Day Avg. Volume166,494
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.85
Price to Sales (P/S)0.44
P/FCF Ratio8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sharp 2025 Revenue ReboundRevenue expanding ~2.6x in 2025 versus 2024 indicates durable demand recovery and scale gains in core animal-health products. Sustained higher sales provide a firmer base for reinvestment, margin recovery, and improved return metrics if the company sustains market share over subsequent quarters.
Conservative & Improving LeverageDeclining debt-to-equity and rising equity signal stronger balance-sheet resilience and financial flexibility. Lower leverage reduces interest burden and supports capacity for capex, acquisitions, or buffer through cyclical downturns, strengthening long-term solvency and funding optionality.
Material Improvement In Cash GenerationPositive OCF and FCF coverage of ~82% of net income in 2025 reflect improved earnings quality and internal funding capacity. Reliable free cash flow supports deleveraging, working-capital needs, and reinvestment without heavy external financing if the company maintains this cash conversion profile.
Bears Say
Historically Volatile EarningsEarnings and cash-flow volatility across recent years undermines predictability for capital allocation and investment returns. Inconsistent profitability complicates long-term planning, increases refinancing risk in adverse cycles, and makes sustaining strategy through downturns more challenging.
Gross-margin CompressionA marked fall in gross margin versus prior years suggests structural pressure from raw-material costs, pricing competition, or product-mix shifts. Lower gross margins reduce the cushion for operating leverage and make net profits more sensitive to cost shocks and competitive pricing over the medium term.
Modest Operating Cash Flow Vs Sales; Uneven HistoryOCF that is modest relative to revenue and a history of periodic negative cash flow indicate ongoing working-capital or reinvestment demands. This can pressure liquidity and force external financing in slower periods, constraining strategic investment and increasing financing cost risk.
Chia Tai Enterprises International News
3839 FAQ
What was Chia Tai Enterprises International Limited’s price range in the past 12 months?
Chia Tai Enterprises International Limited lowest stock price was HK$4.52 and its highest was HK$10.15 in the past 12 months.
What is Chia Tai Enterprises International Limited’s market cap?
Chia Tai Enterprises International Limited’s market cap is HK$2.29B.
When is Chia Tai Enterprises International Limited’s upcoming earnings report date?
Chia Tai Enterprises International Limited’s upcoming earnings report date is Aug 07, 2026 which is in 34 days.
How were Chia Tai Enterprises International Limited’s earnings last quarter?
Chia Tai Enterprises International Limited released its earnings results on May 12, 2026. The company reported HK$0.174 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.174.
Is Chia Tai Enterprises International Limited overvalued?
According to Wall Street analysts Chia Tai Enterprises International Limited’s price is currently Overvalued.
Does Chia Tai Enterprises International Limited pay dividends?
Chia Tai Enterprises International Limited does not currently pay dividends.
What is Chia Tai Enterprises International Limited’s EPS estimate?
Chia Tai Enterprises International Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chia Tai Enterprises International Limited have?
Chia Tai Enterprises International Limited has 240,718,300 shares outstanding.
What happened to Chia Tai Enterprises International Limited’s price movement after its last earnings report?
Chia Tai Enterprises International Limited reported an EPS of HK$0.174 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.292%.
Which hedge fund is a major shareholder of Chia Tai Enterprises International Limited?
Currently, no hedge funds are holding shares in HK:3839
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chia Tai Enterprises International Limited
Chia Tai Enterprises International Limited primarily produces and distributes chlortetracycline (CTC) and related goods. Its extensive international reach covers Mainland China, the Asia Pacific region, the Americas, and Europe. The company's operations are divided into two distinct divisions: Biochemical and Industrial. The Biochemical division focuses on the manufacturing and supply of CTC premix and CTC hydrochloride products. These are employed as feed supplements to encourage livestock growth, prevent or cure animal illnesses, and improve feed conversion, sold under the brands Shihao and Citifac. Conversely, the Industrial segment handles the sales, rental, and maintenance of heavy construction machinery, encompassing items such as excavators, power generators, bulldozers, compactors, and their spare parts. This division also fabricates and markets carburetors and other automotive components for various automobile and motorcycle manufacturers. Founded in 1987, the company maintains its headquarters in Central, Hong Kong, and functions as a subsidiary of Charoen Pokphand Foods Public Company Limited.
Technical Analysis
The United Laboratories International Holdings
―
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---